Hyperalgesia Produced by Intrathecal Substance P and Related Peptides: Desensitization and Cross Desensitization
Overview
Authors
Affiliations
The hyperalgesic effect of intrathecally administered substance P (SP), physalaemin, eledoisin and eledoisin-related peptide (ERP) was investigated in the rat tail flick test. Hyperalgesia produced by SP (2.5-15 micrograms, 1.9-11 nmol) was maximal 10-20 min after injection, lasted 30 min and was dose-related. The effect was mimicked by all of the peptides examined. The rank order of potency was physalaemin greater than SP greater than eledoisin greater than ERP. Desensitization to the hyperalgesic effect of SP was produced by three repeated intrathecal injections. Rats desensitized to SP no longer responded to physalaemin or ERP, indicating cross-desensitization. Phentolamine continued to produce hyperalgesia following such desensitization. The demonstration of a hyperalgesic effect for SP provides further support for a role for SP in nociceptive transmission. The receptor mediating this effect appears to be a SP-P subtype. Cross-desensitization between peptides suggests an action on the same receptor.
Opioids Resistance in Chronic Pain Management.
Morrone L, Scuteri D, Rombola L, Mizoguchi H, Bagetta G Curr Neuropharmacol. 2017; 15(3):444-456.
PMID: 28503117 PMC: 5405610. DOI: 10.2174/1570159X14666161101092822.
Antinociceptive effects of nociceptin/orphanin FQ administered intrathecally in monkeys.
Ko M, Naughton N J Pain. 2009; 10(5):509-16.
PMID: 19231294 PMC: 2797530. DOI: 10.1016/j.jpain.2008.11.006.
Yamamoto T, Nair P, Davis P, Ma S, Navratilova E, Moye S J Med Chem. 2007; 50(12):2779-86.
PMID: 17516639 PMC: 2365895. DOI: 10.1021/jm061369n.
Mazario J, Basbaum A J Neurosci. 2007; 27(4):762-70.
PMID: 17251415 PMC: 6672913. DOI: 10.1523/JNEUROSCI.2992-06.2007.
Role of NK-1 neurotransmission in opioid-induced hyperalgesia.
King T, Gardell L, Wang R, Vardanyan A, Ossipov M, Malan Jr P Pain. 2005; 116(3):276-288.
PMID: 15964684 PMC: 1440305. DOI: 10.1016/j.pain.2005.04.014.